Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.37 |
| ▸ | LPL | P06858 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21101670 | 0.83 | LIPG (0.41) | LIPGLPLALOX5KMT2AMEN1 | |
| SCHEMBL4450495 | 0.79 | ALDH1A1 (0.43) | CYP1A2KDM4EMGLLHSD17B10TDP1 | |
| SCHEMBL29957749 | 0.78 | POLB (0.41) | KMT2AMEN1KDM4ETDP1NPC1 | |
| SCHEMBL45858 | 0.74 | — | — | |
| SCHEMBL18187371 | 0.74 | KDM4E (0.42) | LIPGLPLKDM4EMGLLHSD17B10 | |
| SCHEMBL22852514 | 0.69 | KDM4E (0.49) | CYP1A2KMT2AMEN1KDM4EHSD17B10 | |
| SCHEMBL4411220 | 0.69 | — | — | |
| SCHEMBL316086 | 0.69 | — | — | |
| SCHEMBL18891813 | 0.68 | KDM4E (0.32) | KDM4EMGLLHSD17B10TDP1 | |
| SCHEMBL4924292 | 0.66 | BCHE (0.33) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106636043-B | Method for producing protease | 广州立白企业集团有限公司 | 2020-04-07 | — | — | CN | claimed |
| US-20240279627-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2024-08-22 | — | — | US | disclosed |
| US-20230049452-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2023-02-16 | — | — | US | disclosed |
| EP-4090727-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | Danisco US Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2021146255-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2021-07-22 | — | — | WO | disclosed |
| EP-3842531-A1 | COMPOSITIONS AND METHOD COMPRISING A LIPOLYTIC ENZYME VARIANT | Danisco US Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3833731-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | Danisco US Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-10920204-B2 | Compositions and methods comprising a lipolytic enzyme variant | DANISCO US INC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20150291944-A1 | COMPOSITIONS AND METHODS COMPRISING A LIPOLYTIC ENZYME VARIANT | DANISCO US INC. (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2906691-A1 | COMPOSITIONS AND METHODS COMPRISING A LIPOLYTIC ENZYME VARIANT | Danisco US Inc. (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2751263-A1 | COMPOSITIONS AND METHODS COMPRISING A LIPOLYTIC ENZYME VARIANT | Danisco US Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20140187468-A1 | Compositions and Methods Comprising a Lipolytic Enzyme Variant | DANISCO US INC. (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2014100018-A1 | NOVEL MANNANASE, COMPOSITIONS AND METHODS OF USE THEREOF | DANISCO US INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| CN-103646191-A | Virtual screening method for micromolecular reversible inhibitor of alkaline metalloproteinase from flavobacterium YS-80-122 | YELLOW SEA FISHERIES RES INST CHINESE ACAD FISHERY SCIENCES | 2014-03-19 | — | — | CN | disclosed |
| WO-2013033318-A1 | COMPOSITIONS AND METHODS COMPRISING A LIPOLYTIC ENZYME VARIANT | DANISCO US INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | disclosed |
| US-7524870-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, GSK3A | LIPG 896/4885LPL 616/4885ALOX5 1196/4885 |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GYS2, GYS1, GSK3A | LIPG 896/4885LPL 616/4885ALOX5 1196/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | LIPG 779/4885LPL 1464/4885ALOX5 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.